SIC – No underlying medical conditions
The population is composed of patients with no underlying medical conditions who received at least one dose of a COVID-19 vaccine and experienced rare and medically significant adverse events following immunization (AEFIs) without an alternate cause for their symptoms.
The population is composed of patients with no underlying medical conditions who received at least one dose of a COVID-19 vaccine and experienced rare and medically significant adverse events following immunization (AEFIs) without an alternate cause for their symptoms.
-
Newborns
-
-
Twins
-
-
Countries
-
-
Territory
-
Halifax, Quebec City, Montreal, Sherbrooke, Ottawa, Toronto, Hamilton, Saskatoon, Edmonton, Calgary, Vancouver
-
Ethnic Origin
-
-
Health Status
-
- Participants are included if they experienced any of the following adverse effects after receiving a COVID-19 vaccine: anaphylaxis (onset <24 hours after immunization), immediate hypersensitivity (onset <4 hours after immunization), type III or IV hypersensitivity reactions, severe cutaneous or systemic reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis), seizure or significant worsening of seizures in those with an underlying seizure disorder, Guillain-Barré Syndrome, acute disseminated encephalomyelitis, transverse myelitis or other suspected demyelinating condition, aseptic meningitis, encephalitis, thrombocytopenia, deep vein thrombosis, pulmonary embolism, stroke, heart failure and cardiogenic shock, cardiomyopathy, arrhythmia, myocarditis, pericarditis, acute kidney injury, acute liver injury, acute respiratory distress syndrome, other severe local or systemic symptoms causing work/school absenteeism or significant decline in function, mobility or cognition and requiring immediate medical attention, or severe COVID-19 requiring hospitalization with onset >2 weeks post-immunization.
-
Other Criteria
-
Patients with vaccine hesitancy or concerns will be excluded from the study.
-
Sources of recruitment
-
-
Specific Population
-
-
Supplementary Information
-
Participants are referred to the study by a healthcare provider (physician, nurse practitioner, public health physician).
-
Number of Participants
-
-
Number of Participants with Biological Samples
-